Digestive Diseases and Sciences

, Volume 55, Issue 6, pp 1696–1703 | Cite as

Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease

  • Jeffrey Tang
  • Omar Sharif
  • Chetan Pai
  • Ann L. Silverman
Original Article

Abstract

Background

Individuals with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer (CRC) compared with the general population. Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support.

Aim

Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients.

Methods

IBD patients with CRC were matched to controls by IBD type, age at diagnosis, sex, race, extent of disease, and disease duration. We compared body mass index, family history of IBD, family history of CRC, tobacco use, and cumulative and daily use of aminosalicylates, immunomodulators, folic acid, steroids, and nonsteroidal anti-inflammatory drugs. Statistical analysis was performed with logistic regression and receiver operating characteristic (ROC) curves.

Results

Of 1,594 IBD patients, 30 CRC patients were identified. Of these, 18 CRC patients were matched to 30 controls. More control patients used a cumulative aminosalicylate dose of ≥4,500 g (46.6% versus 5.6%; P = 0.047), folic acid (40.0% versus 16.7%; P = 0.002), cumulative folic acid dose of ≥1,400 mg (30.0% versus 11.1%; P = 0.014), and average daily folic acid dose of ≥1 mg (30.0% versus 16.7%; P = 0.002) compared with CRC patients. Multivariate analysis showed that a cumulative aminosalicylate dose of ≥4,500 g reduced the risk of CRC by 97.6% (P = 0.047). Folic acid reduced CRC risk by 89% (P = 0.002).

Conclusions

Aminosalicylate and folic acid use may decrease the risk of CRC among IBD patients.

Keywords

Inflammatory bowel disease Colorectal neoplasm Mesalamine Folic acid Ulcerative colitis Crohn’s disease 

Notes

Acknowledgments

This study was funded in full by a grant from Proctor and Gamble (E07058).

Conflict of Interest

All other authors confirm that there are no personal interests.

References

  1. 1.
    Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease. Cancer. 2001;91:854–862.CrossRefPubMedGoogle Scholar
  2. 2.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.CrossRefPubMedGoogle Scholar
  3. 3.
    Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. N Engl J Med. 1990;323:1228–1233.PubMedGoogle Scholar
  4. 4.
    Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in crohn’s disease and ulcerative colitis. Cancer. 1981;48:2742–2745.CrossRefPubMedGoogle Scholar
  5. 5.
    Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:459–477.CrossRefPubMedGoogle Scholar
  6. 6.
    Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:1–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Jess T, Loftus EV, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota. Am J Gastroenterol. 2007;102:829–836.CrossRefPubMedGoogle Scholar
  8. 8.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.CrossRefPubMedGoogle Scholar
  9. 9.
    Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.CrossRefPubMedGoogle Scholar
  10. 10.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2004;99:1371–1385.CrossRefPubMedGoogle Scholar
  11. 11.
    Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784–2788.CrossRefPubMedGoogle Scholar
  12. 12.
    Carrier J, Medline A, Sohn KJ, et al. Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin w- and beta (2) - microglobulin-deficient mice. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt1):1262–12167.PubMedGoogle Scholar
  13. 13.
    Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:675–712.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheng Y, Desreumaux P. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol. 2005;11:309–314.PubMedGoogle Scholar
  15. 15.
    Clapper ML, Gary MA, Coudry RA, et al. 5-Aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2008;14:1341–1347.CrossRefPubMedGoogle Scholar
  16. 16.
    Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis. 2003;18:392–400.CrossRefPubMedGoogle Scholar
  17. 17.
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145–153.CrossRefPubMedGoogle Scholar
  18. 18.
    Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplements on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112:29–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Moody GA, Jayanthi V, Probert CSJ, et al. Long-term therapy with sulfasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179–1183.CrossRefPubMedGoogle Scholar
  20. 20.
    Rubin DT, Cruz-Correa MR, Gashe C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update. Inflamm Bowel Dis. 2008;14:265–274.CrossRefPubMedGoogle Scholar
  21. 21.
    Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346–1350.CrossRefPubMedGoogle Scholar
  22. 22.
    Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med. 2001;138:164–176.CrossRefPubMedGoogle Scholar
  23. 23.
    Ryan BM, Russel MGVM, Langholz E, et al. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol. 2003;98:1682–1687.CrossRefPubMedGoogle Scholar
  24. 24.
    Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-aminosalicylatic therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367–371.CrossRefPubMedGoogle Scholar
  25. 25.
    Van Bodegraven AA, Mulder CJJ. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol. 2006;12:6115–6123.PubMedGoogle Scholar
  26. 26.
    Van Staa TP, Card T, Logan RF, et al. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573–1578.CrossRefPubMedGoogle Scholar
  27. 27.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systemic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–1353.CrossRefPubMedGoogle Scholar
  28. 28.
    Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–1362.CrossRefPubMedGoogle Scholar
  29. 29.
    Makoul G, Curry RH, Tang PC. The use of electronic medical records: communication patterns in outpatient encounters. J Am Med Inform Assoc. 2001;8:610–615.PubMedGoogle Scholar
  30. 30.
    Bergman R, Parkes M. Systemic review: the use of mesalamine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841–845.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jeffrey Tang
    • 1
  • Omar Sharif
    • 1
  • Chetan Pai
    • 1
  • Ann L. Silverman
    • 1
  1. 1.Department of Internal Medicine, Division of GastroenterologyHenry Ford Health System, Henry Ford HospitalDetroitUSA

Personalised recommendations